Expanding Clinical Trial Access Amid DEI Challenges
Cetuximab Plus Chemotherapy May Improve Colorectal Cancer Outcomes
Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says
Health System Policy Failures Drive Cervical Cancer Disparities in Rural South
Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation
Watch the series now!
Identifying Good Candidates for Histotripsy to Treat Liver Tumors
Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed
Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer
The Need for Payer Support in Overcoming Cancer Care Disparities
Geographic Barriers Impede Access to Novel Cancer Treatments
Fueling Cancer Research Breakthroughs With Patient Contributions
Addressing Financial Toxicity and Clinical Trial Disparities in Community Oncology
Enfortumab Vedotin With or Without Pembrolizumab Delivers Promising Responses for Upper Tract Urothelial Cancer
Receiving NADT for 6 Months Doesn’t Impact Outcomes in Intermediate-Risk Prostate Cancer After EBRT
The “Secret Sauce” in Oncology: The Partnership Between Clinicians and AI
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
Oncology Onward: A Conversation With OneOncology’s Dr Jeff Patton
Health Equity Conversations: Improving Diversity of Oncology Care Staff
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
Reforming Oncology Care Payments: Interviews From the QCCA Leadership Summit
What Are the Next Steps for Collaboration, Accountability in Oncology Care First?
KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges
Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Study Finds Declining SCLC Incidence, but Stagnant Survival Rates